Sylvain Lanthier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sylvain Lanthier has a total of 310 co-authors. Here are the top co-authors by number of shared publications:
- François Guilbert
Service of Neuroradiology (D.I., D.R., A.W., W.B., A.D., M.K., L.L.-G., F.G., J.R.), Department of Radiology, Centre Hospitalier de l’Université de Montréal, Montreal, Québec, Canada
4 shared publications - Alain Weill
Department of Radiology, Centre hospitalier de l'Université de Montréal (CHUM), Hopital Notre-Dame, Montreal, Quebec, Canada
3 shared publications - Aleksandra Pikula
Toronto Western Hospital (A.P.), University of Toronto, ON, Canada
3 shared publications Céline Chayer
Department of Neurosciences, Université de Montréal, Montreal, Canada
3 shared publications- Daniel Roy
Centre Hospitalier de l’Université de Montréal, Montreal, Canada
3 shared publications - Daniel Strbian
Department of Neurology, Helsinki University Hospital and University of Helsinki , Helsinki
3 shared publications
Latest Publications
- Open Access
- 4 February 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (2) , 767
Publisher Correction: Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial
- 4 February 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (2) , 767
Open AccessPublisher Correction: Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial
- Top Cited PapersOpen Access
- 7 January 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (1) , 297-305
Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial
Individuals with atrial fibrillation (AF) are at increased risk of stroke, cognitive impairment and dementia. Observational studies suggest that anticoagulation may reduce the risk of cognitive decline in patients with AF and elevated thromboembolic risk, implicating subclinical cerebral emboli as a potential mechanistic link. Whether anticoagulation prevents cognitive deterioration in patients with AF at low risk of stroke remains uncertain. Here we conducted a multicenter, double-blind, placebo-controlled trial in which participants with AF and low thromboembolic risk (CHA2DS2-VASc scores of 0 or 1, excluding female sex) were randomized 1:1 to receive rivaroxaban 15 mg daily or placebo. The primary outcome was a composite of cognitive decline (≥2-point drop in Montreal Cognitive Assessment), stroke or transient ischemic attack with a motor deficit or aphasia. The trial was halted after meeting the predetermined futility criterion following a planned interim analysis, with 1,235 of the intended 1,424 participants (919 men; 316 women) enrolled. Over a median follow-up of 3.7 years, the primary outcome occurred in 256 (20.7%) participants, at an annual rate of 7.0% with rivaroxaban versus 6.4% with placebo, yielding a hazard ratio of 1.10 (95% confidence interval (0.86–1.40); P = 0.46). Conditional power analysis indicated a 1.2% probability of achieving a statistically significant treatment effect if the trial had been continued to its planned total of 410 events. Major bleeding occurred in two patients treated with rivaroxaban (0.09% per year) and five patients treated with placebo (0.21% per year). In conclusion, despite the high incidence of cognitive decline observed among patients with AF and low stroke risk, the BRAIN-AF trial, which tested a low dose of rivaroxaban to prevent stroke, transient ischemic attack and cognitive decline in patients with prior AF, was stopped early due to futility. ClinicalTrials.gov registration: NCT02387229.
- 7 January 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (1) , 297-305
Top Cited PapersOpen AccessAnticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial
Individuals with atrial fibrillation (AF) are at increased risk of stroke, cognitive impairment and dementia. Observational studies suggest that anticoagulation may reduce the risk of cognitive decline in patients with AF and elevated thromboembolic risk, implicating subclinical cerebral emboli as a potential mechanistic link. Whether anticoagulation prevents cognitive deterioration in patients with AF at low risk of stroke remains uncertain. Here we conducted a multicenter, double-blind, placebo-controlled trial in which participants with AF and low thromboembolic risk (CHA2DS2-VASc scores of 0 or 1, excluding female sex) were randomized 1:1 to receive rivaroxaban 15 mg daily or placebo. The primary outcome was a composite of cognitive decline (≥2-point drop in Montreal Cognitive Assessment), stroke or transient ischemic attack with a motor deficit or aphasia. The trial was halted after meeting the predetermined futility criterion following a planned interim analysis, with 1,235 of the intended 1,424 participants (919 men; 316 women) enrolled. Over a median follow-up of 3.7 years, the primary outcome occurred in 256 (20.7%) participants, at an annual rate of 7.0% with rivaroxaban versus 6.4% with placebo, yielding a hazard ratio of 1.10 (95% confidence interval (0.86–1.40); P = 0.46). Conditional power analysis indicated a 1.2% probability of achieving a statistically significant treatment effect if the trial had been continued to its planned total of 410 events. Major bleeding occurred in two patients treated with rivaroxaban (0.09% per year) and five patients treated with placebo (0.21% per year). In conclusion, despite the high incidence of cognitive decline observed among patients with AF and low stroke risk, the BRAIN-AF trial, which tested a low dose of rivaroxaban to prevent stroke, transient ischemic attack and cognitive decline in patients with prior AF, was stopped early due to futility. ClinicalTrials.gov registration: NCT02387229.
- Open Access
- 12 December 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (12) , e70462
Markers of Giant Cell Arteritis in Patients Presenting With Ischemic Stroke: A Scoping Review
Background: In patients with giant cell arteritis (GCA), 2.8%–8.2% present with ischemic stroke (IS) or transient ischemic attack (TIA). GCA diagnosis may be overlooked, and immunosuppressive treatment delayed if typical symptoms are absent or if a common cause of IS coexists. This study aimed to identify potential markers of GCA through clinical evaluation and baseline investigation of IS/TIA patients. Methods: Two authors independently conducted a scoping review using MEDLINE and EMBASE databases to identify patients diagnosed with GCA after presenting with IS/TIA. All articles, including the gray literature, were considered from January 2000 onwards if individualized data were described. Only cases of IS/TIA with GCA later diagnosed as the etiology were included for analysis. Results: A total of 101 publications were included, pooling data on 141 patients for analysis. The mean age was 73.6 years, and 61 were women. Patients experienced either single (56.0%) or multiple IS/TIA events (44.0%). Associated symptoms included GCA‐related pain, such as headaches (50.4%), constitutional symptoms (47.5%), and temporal artery inflammation (27.0%). Neurological deficits involved corticospinal tracts (41.8%), and cerebellar functions (53.2%). Most patients had clinical or radiological evidence of vertebrobasilar involvement (83.7%). Multifocal involvement of the vertebrobasilar and carotid territories was supported when combining clinical‐radiological manifestations (41.1%). Recurrent events were common (44.0%). Conclusion: GCA should be considered in IS/TIA patients aged ≥ 50 years with vertebrobasilar or multiterritorial involvement, or recurrent IS/TIA despite secondary prevention.
- 12 December 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (12) , e70462
Open AccessMarkers of Giant Cell Arteritis in Patients Presenting With Ischemic Stroke: A Scoping Review
Background: In patients with giant cell arteritis (GCA), 2.8%–8.2% present with ischemic stroke (IS) or transient ischemic attack (TIA). GCA diagnosis may be overlooked, and immunosuppressive treatment delayed if typical symptoms are absent or if a common cause of IS coexists. This study aimed to identify potential markers of GCA through clinical evaluation and baseline investigation of IS/TIA patients. Methods: Two authors independently conducted a scoping review using MEDLINE and EMBASE databases to identify patients diagnosed with GCA after presenting with IS/TIA. All articles, including the gray literature, were considered from January 2000 onwards if individualized data were described. Only cases of IS/TIA with GCA later diagnosed as the etiology were included for analysis. Results: A total of 101 publications were included, pooling data on 141 patients for analysis. The mean age was 73.6 years, and 61 were women. Patients experienced either single (56.0%) or multiple IS/TIA events (44.0%). Associated symptoms included GCA‐related pain, such as headaches (50.4%), constitutional symptoms (47.5%), and temporal artery inflammation (27.0%). Neurological deficits involved corticospinal tracts (41.8%), and cerebellar functions (53.2%). Most patients had clinical or radiological evidence of vertebrobasilar involvement (83.7%). Multifocal involvement of the vertebrobasilar and carotid territories was supported when combining clinical‐radiological manifestations (41.1%). Recurrent events were common (44.0%). Conclusion: GCA should be considered in IS/TIA patients aged ≥ 50 years with vertebrobasilar or multiterritorial involvement, or recurrent IS/TIA despite secondary prevention.
- Open Access
- 15 July 2025
- Published by Elsevier in Structural Heart
- Vol. 9 (8) , 100699
Patent Foramen Ovale Closure in Older Patients With Cryptogenic Stroke: Current Evidence and Next Steps
- 15 July 2025
- Published by Elsevier in Structural Heart
- Vol. 9 (8) , 100699
Open AccessPatent Foramen Ovale Closure in Older Patients With Cryptogenic Stroke: Current Evidence and Next Steps
- Top Cited Papers
- 1 November 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (11) , 2724-2736
Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis
BACKGROUND: Emerging data suggest that direct oral anticoagulants may be a suitable choice for anticoagulation for cerebral venous thrombosis (CVT). However, conducting high-quality trials in CVT is challenging as it is a rare disease with low rates of adverse outcomes such as major bleeding and functional dependence. To facilitate the design of future CVT trials, SECRET (Study of Rivaroxaban for Cerebral Venous Thrombosis) assessed (1) the feasibility of recruitment, (2) the safety of rivaroxaban compared with standard-of-care anticoagulation, and (3) patient-centered functional outcomes. METHODS: This was a phase II, prospective, open-label blinded-end point 1:1 randomized trial conducted at 12 Canadian centers. Participants were aged ≥18 years, within 14 days of a new diagnosis of symptomatic CVT, and suitable for oral anticoagulation; they were randomized to receive rivaroxaban 20 mg daily, or standard-of-care anticoagulation (warfarin, target international normalized ratio, 2.0–3.0, or low-molecular-weight heparin) for 180 days, with optional extension up to 365 days. Primary outcomes were annual rate of recruitment (feasibility); and a composite of symptomatic intracranial hemorrhage, major extracranial hemorrhage, or mortality at 180 days (safety). Secondary outcomes included recurrent venous thromboembolism, recanalization, clinically relevant nonmajor bleeding, and functional and patient-reported outcomes (modified Rankin Scale, quality of life, headache, mood, fatigue, and cognition) at days 180 and 365. RESULTS: Fifty-five participants were randomized. The rate of recruitment was 21.3 participants/year; 57% of eligible candidates consented. Median age was 48.0 years (interquartile range, 38.5–73.2); 66% were female. There was 1 primary event (symptomatic intracranial hemorrhage), 2 clinically relevant nonmajor bleeding events, and 1 recurrent CVT by day 180, all in the rivaroxaban group. All participants in both arms had at least partial recanalization by day 180. At enrollment, both groups on average reported reduced quality of life, low mood, fatigue, and headache with impaired cognitive performance. All metrics improved markedly by day 180. CONCLUSIONS: Recruitment targets were reached, but many eligible participants declined randomization. There were numerically more bleeding events in patients taking rivaroxaban compared with control, but rates of bleeding and recurrent venous thromboembolism were low overall and in keeping with previous studies. Participants had symptoms affecting their well-being at enrollment but improved over time. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03178864.
- 1 November 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (11) , 2724-2736
Top Cited PapersStudy of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis
BACKGROUND: Emerging data suggest that direct oral anticoagulants may be a suitable choice for anticoagulation for cerebral venous thrombosis (CVT). However, conducting high-quality trials in CVT is challenging as it is a rare disease with low rates of adverse outcomes such as major bleeding and functional dependence. To facilitate the design of future CVT trials, SECRET (Study of Rivaroxaban for Cerebral Venous Thrombosis) assessed (1) the feasibility of recruitment, (2) the safety of rivaroxaban compared with standard-of-care anticoagulation, and (3) patient-centered functional outcomes. METHODS: This was a phase II, prospective, open-label blinded-end point 1:1 randomized trial conducted at 12 Canadian centers. Participants were aged ≥18 years, within 14 days of a new diagnosis of symptomatic CVT, and suitable for oral anticoagulation; they were randomized to receive rivaroxaban 20 mg daily, or standard-of-care anticoagulation (warfarin, target international normalized ratio, 2.0–3.0, or low-molecular-weight heparin) for 180 days, with optional extension up to 365 days. Primary outcomes were annual rate of recruitment (feasibility); and a composite of symptomatic intracranial hemorrhage, major extracranial hemorrhage, or mortality at 180 days (safety). Secondary outcomes included recurrent venous thromboembolism, recanalization, clinically relevant nonmajor bleeding, and functional and patient-reported outcomes (modified Rankin Scale, quality of life, headache, mood, fatigue, and cognition) at days 180 and 365. RESULTS: Fifty-five participants were randomized. The rate of recruitment was 21.3 participants/year; 57% of eligible candidates consented. Median age was 48.0 years (interquartile range, 38.5–73.2); 66% were female. There was 1 primary event (symptomatic intracranial hemorrhage), 2 clinically relevant nonmajor bleeding events, and 1 recurrent CVT by day 180, all in the rivaroxaban group. All participants in both arms had at least partial recanalization by day 180. At enrollment, both groups on average reported reduced quality of life, low mood, fatigue, and headache with impaired cognitive performance. All metrics improved markedly by day 180. CONCLUSIONS: Recruitment targets were reached, but many eligible participants declined randomization. There were numerically more bleeding events in patients taking rivaroxaban compared with control, but rates of bleeding and recurrent venous thromboembolism were low overall and in keeping with previous studies. Participants had symptoms affecting their well-being at enrollment but improved over time. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03178864.
- 12 October 2022
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 31 (12) , 106780
Ischemic stroke is a potential complication of uncontrolled inflammation in mevalonate kinase deficiency – A case report
- 12 October 2022
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 31 (12) , 106780
Ischemic stroke is a potential complication of uncontrolled inflammation in mevalonate kinase deficiency – A case report
- Open Access
- 1 December 2020
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 5 (4) , 402-413
Non-invasive brain stimulation as add-on therapy for subacute post-stroke aphasia: a randomized trial (NORTHSTAR)
Non-invasive brain stimulation (NIBS) with speech therapy might improve recovery from post-stroke aphasia. This three-armed sham-controlled blinded prospective proof-of-concept study tested 1 Hz subthreshold repetitive transcranial magnetic stimulation (rTMS) and 2-mA cathodal transcranial direct current stimulation (ctDCS) on the right pars triangularis in subacute post-stroke aphasia. Sixty-three patients with left middle cerebral artery infarcts were recruited in five hospitals (Canada/United States/Germany, 01–2014/03–2018) and randomized to receive rTMS (N = 20), ctDCS (N = 24) or sham stimulation (N = 19) with ST for 10 days. Primary outcome variables were Z-score changes in naming, semantic fluency and comprehension tests and adverse event frequency. Secondary outcome variable was the percent change in the Unified Aphasia Score. Intention-to-treat analyses tested between-group effects at days 1 and 30 post-treatment with a pre-planned subgroup analysis for lesion location (affecting Broca’s area or not). Naming was significantly improved by rTMS (median = 1.91/interquartile range = 0.77/p = .01) at 30 days versus ctDCS (median = 1.11/interquartile range = 1.51) and sham stimulation (median = 1.02/interquartile range = 1.71). All other primary results were non-significant. The rTMS effect was driven by the patient subgroup with intact Broca’s area where NIBS tended to improve UnAS (median = 33.2%/interquartile range = 46.7%/p = .062) versus sham stimulation (median = 12.5%/interquartile range = 7.9%) at day 30. Conversely, in patients with infarcted Broca’s area, UnAS tended to improve more with sham stimulation (median = 75.0%/interquartile range = 86.9%/p = .053) versus NIBS (median = 12.7%/interquartile range = 31.7). Conclusion: We found a delayed positive effect of low-frequency rTMS targeting the right pars triangularis on the recovery of naming performance in subacute post-stroke aphasia. This intervention may be beneficial only in patients with morphologically intact Broca’s area.
- 1 December 2020
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 5 (4) , 402-413
Open AccessNon-invasive brain stimulation as add-on therapy for subacute post-stroke aphasia: a randomized trial (NORTHSTAR)
Non-invasive brain stimulation (NIBS) with speech therapy might improve recovery from post-stroke aphasia. This three-armed sham-controlled blinded prospective proof-of-concept study tested 1 Hz subthreshold repetitive transcranial magnetic stimulation (rTMS) and 2-mA cathodal transcranial direct current stimulation (ctDCS) on the right pars triangularis in subacute post-stroke aphasia. Sixty-three patients with left middle cerebral artery infarcts were recruited in five hospitals (Canada/United States/Germany, 01–2014/03–2018) and randomized to receive rTMS (N = 20), ctDCS (N = 24) or sham stimulation (N = 19) with ST for 10 days. Primary outcome variables were Z-score changes in naming, semantic fluency and comprehension tests and adverse event frequency. Secondary outcome variable was the percent change in the Unified Aphasia Score. Intention-to-treat analyses tested between-group effects at days 1 and 30 post-treatment with a pre-planned subgroup analysis for lesion location (affecting Broca’s area or not). Naming was significantly improved by rTMS (median = 1.91/interquartile range = 0.77/p = .01) at 30 days versus ctDCS (median = 1.11/interquartile range = 1.51) and sham stimulation (median = 1.02/interquartile range = 1.71). All other primary results were non-significant. The rTMS effect was driven by the patient subgroup with intact Broca’s area where NIBS tended to improve UnAS (median = 33.2%/interquartile range = 46.7%/p = .062) versus sham stimulation (median = 12.5%/interquartile range = 7.9%) at day 30. Conversely, in patients with infarcted Broca’s area, UnAS tended to improve more with sham stimulation (median = 75.0%/interquartile range = 86.9%/p = .053) versus NIBS (median = 12.7%/interquartile range = 31.7). Conclusion: We found a delayed positive effect of low-frequency rTMS targeting the right pars triangularis on the recovery of naming performance in subacute post-stroke aphasia. This intervention may be beneficial only in patients with morphologically intact Broca’s area.
- Open Access
- 6 June 2020
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 51 (1) , 25-28
Hyperacute multi-organ thromboembolic storm in COVID-19: a case report
Acute viral pneumonia, hypoxemic respiratory failure and severe inflammatory response are hallmarks of severe coronavirus disease 2019 (COVID-19). The COVID-19-associated inflammatory state may further lead to symptomatic thromboembolic complications despite prophylaxis. We report a 66-year-old female patient with post-mortem diagnosis of COVID-19 who presented progressive livedo racemosa, acute renal failure and myocardial injury, as well as an absence of respiratory symptoms. Transthoracic echocardiography showed severe spontaneous echo contrast in the right cardiac chambers and right-sided cardiac overload presumed to result from pulmonary microvascular thrombosis or embolism. d-dimer levels were increased. The patient developed an acute ischemic stroke and died 2 days following presentation despite therapeutic anticoagulation. Her predominantly thromboembolic presentation supports the concept of coronavirus infection of endothelial cells and hypercoagulability, or COVID-19 endotheliitis. The case we report highlights that COVID-19-associated hyperacute multi-organ thromboembolic storm may precede or present disproportionately to respiratory involvement.
- 6 June 2020
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 51 (1) , 25-28
Open AccessHyperacute multi-organ thromboembolic storm in COVID-19: a case report
Acute viral pneumonia, hypoxemic respiratory failure and severe inflammatory response are hallmarks of severe coronavirus disease 2019 (COVID-19). The COVID-19-associated inflammatory state may further lead to symptomatic thromboembolic complications despite prophylaxis. We report a 66-year-old female patient with post-mortem diagnosis of COVID-19 who presented progressive livedo racemosa, acute renal failure and myocardial injury, as well as an absence of respiratory symptoms. Transthoracic echocardiography showed severe spontaneous echo contrast in the right cardiac chambers and right-sided cardiac overload presumed to result from pulmonary microvascular thrombosis or embolism. d-dimer levels were increased. The patient developed an acute ischemic stroke and died 2 days following presentation despite therapeutic anticoagulation. Her predominantly thromboembolic presentation supports the concept of coronavirus infection of endothelial cells and hypercoagulability, or COVID-19 endotheliitis. The case we report highlights that COVID-19-associated hyperacute multi-organ thromboembolic storm may precede or present disproportionately to respiratory involvement.
- 1 December 2018
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 58, 25-29
3T MRI study discloses high intrafamilial variability in CADASIL due to a novel NOTCH3 mutation
- 1 December 2018
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 58, 25-29
3T MRI study discloses high intrafamilial variability in CADASIL due to a novel NOTCH3 mutation